JEFFERSON CITY — Missouri State Representative Michael Davis (R-Kansas City) has filed House Bill 2429, which expands Missouri’s Right to Try statute to include Schedule 1 investigational drugs, with a focus on psychedelic drugs including psilocybin, MDMA, LSD, and ibogaine.
Representative Davis said, “There is emerging interest and significant clinical research supporting the safety and efficacy of psychedelic drugs for PTSD, traumatic injury therapy, and numerous other conditions. Because the FDA has not taken action to reschedule these drugs and make them generally available, I am working to make these drugs available through Missouri’s investigational drug access statute. Importantly, House Bill 2429 aligns Missouri law with the federal Right to Try law passed by a conservative majority in Congress and signed by President Trump in 2018.”
Dr. Zinia Thomas MD of Radiance Ketamine in St. Louis, Missouri, said, “The last few years of the COVID pandemic has created an epidemic of severe depression and other serious mental issues. Representative Davis’s bill gives us desperately needed clinically validated options to address a range of mental health conditions and hopefully stem the tide as suicides increase year over year.”
Douglas K. Gordon, Chief Executive Officer of Silo Wellness, a publicly-traded company (OTCQB: SILFF) providing psilocybin retreats in Jamaica, said, “Americans seeking the powerful therapeutic benefits of psychedelic medicines often have no choice but to leave the country to access these novel treatments. Representative Davis’s leadership will hopefully result in American citizens finding relief in the American heartland. We call on Missouri’s lawmakers to take this bill under consideration in 2022.”
Larry Shapiro PhD of Quantum Behavioral in St. Louis said, “As a clinical psychologist with extensive experience treating combat-related PTSD with our veteran community, as well as depression and anxiety, I strongly believe that Rep. Davis’ bill offers an opportunity for Missouri veterans and those suffering from mental illness’ that haven’t responded to traditional treatments to have access to novel and effective therapies. Psychedelic medicines and integration therapy have demonstrated enormous potential to address the mental health needs in our state and across the country. I call on the Missouri General Assembly to advance this proposal in 2022.”